



## **Stereotaxis Technologies to be Highlighted at Society for Cardiac Robotic Navigation's Inaugural Meeting in Amsterdam**

October 18, 2016

ST. LOUIS, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that its magnetic and robotic navigation systems will be represented at the inaugural meeting of the Society for Cardiac Robotic Navigation (SCRN) in Amsterdam, October 20 and 21. The meeting will bring together distinguished physicians experienced in the application of robotically navigated cardiac ablation to discuss, debate and educate on both the current role and future possibilities of robotics in clinical electrophysiology (EP).

Founded in 2015, the Society for Cardiac Robotic Navigation aims to establish a platform for users of remote technologies in cardiology to share best practices, clinical evidence and information on the latest innovations, while building a network of experts intent on driving the adoption of robotics in interventional medicine. Members have published numerous papers comparing remote magnetic navigation to conventional manual ablation in a wide range of EP procedures. The SCRN is led by Founder and President Dr. Tamas Szili-Torök of Erasmus Medical Center (Netherlands), and Co-founders Dr. Bruno Schwagten of ZNA Middelheim (Belgium) and Dr. Georg Nölker of Ruhr-Universität Bochum (Germany).

"These leaders have experienced first-hand the power of robotic technologies to produce high levels of efficiency, efficacy and safety in ablation therapy and have recognized their underrepresentation in daily clinical practice," said William C. Mills, Stereotaxis Chief Executive Officer and Chairman. "We are pleased that our products will be featured at the first official meeting of the SCRN and excited about its potential to effect greater awareness and acceptance of remote, automated solutions as the standard of care in cardiac ablation."

### **About Stereotaxis**

Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core *Epoch*<sup>®</sup> Solution includes the *Niobe*<sup>®</sup> ES remote magnetic navigation system, the *Odyssey*<sup>®</sup> portfolio of lab optimization, networking and patient information management systems, and the *Vdrive*<sup>®</sup> robotic navigation system and consumables.

The core components of Stereotaxis' systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono<sup>™</sup> ICE catheter manipulator, V-Loop<sup>™</sup> variable loop catheter manipulator, and V-CAS<sup>™</sup> catheter advancement system have received clearance in the United States, Canada, and the European Union. The V-CAS Deflect<sup>™</sup> catheter advancement system has been CE Marked for sale in the European Union. For more information, please visit [www.stereotaxis.com](http://www.stereotaxis.com).

*This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional financing, in either case on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.*

STXS Company Contact:  
Martin Stammer  
Chief Financial Officer  
314-678-6155

STXS Investor Contact:  
Todd Kehrli / Jim Byers  
MKR Group, Inc.  
323-468-2300  
[stxs@mkr-group.com](mailto:stxs@mkr-group.com)



Stereotaxis, Inc.